Arrayuys’ Focused Ultrasound Therapy System Gets Health Canada Approval

Arrayus Technologies Inc. announced that its MRI-guided focused ultrasound system has been granted approval by Health Canada for the ablation of uterine fibroid tissue. Following the success of its first-in-human clinical trial, this approval paves the way for Canadian healthcare providers to offer a safe, non-invasive alternative to traditional surgical options for this common gynecological condition.

Arrayus' focused ultrasound system, offers a transformative approach to non-invasive therapy, using high-precision acoustic energy to target and treat tissue deep within the body without the need for incisions or general anesthesia. Built with the world's first clinically-available fully phased array, intuitive treatment planning tools and real-time therapy monitoring, the system enables clinicians to tailor treatments based on individual disease characteristics, ensuring precision while protecting nearby healthy tissue.

"I am incredibly proud of our team for achieving this monumental first milestone" said James O'Reilly, CEO of Arrayus. "Securing Health Canada approval marks a pivotal moment in the evolution of our technology but it's only the beginning. Our platform has the potential to transform patient care across multiple medical specialties. We are committed to pushing the boundaries of medical innovation to reduce the burden on the healthcare system and improve patient outcomes worldwide."

Arrayus is actively expanding the potential applications for its focused ultrasound platform. The company has clinical trials underway to evaluate the use of its system in various oncological settings, and is working with healthcare professionals, researchers, and industry partners to explore its use in neurology, women's health, and beyond.